Estudio presentado por el Dr. Andre Lamy en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.Cristiano Amarelli
The ALMA score from Loforte et al. presented at the ASAIO meeting in Chicago on June 24th. An Useful Decision Supporting Tool available bedside to predict right ventricular failure and even to modify the surgical planning to support/protect right heart and warranting better outcome.
Asaio 2017: Predicting Right Ventricular Failure in CF-LVAD Era.Cristiano Amarelli
The ALMA score from Loforte et al. presented at the ASAIO meeting in Chicago on June 24th. An Useful Decision Supporting Tool available bedside to predict right ventricular failure and even to modify the surgical planning to support/protect right heart and warranting better outcome.
Cytori CEO Chris Calhoun presents as part of the "Cardiovascular, AMI & PAD" panel on the Regenerative Medicine Insight Track at the Biotech Showcase on January 10, 2012
Estudio presentado por la Dra. Anna Toso en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
Estudio presentado por el Dr. Gilles Montalescot en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
Quirofano hibrido por Dr. Gerardo Sela.gerardo sela
Concepto de lo que es una Quirofano hibrido, es decir una sala de hemodinamia y un quirofano con lo mas sofisticado de ambas tecnologias para atencion de padecimientos que regularmente llevarian dos tiempos.
Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...CardioTeca
Autor: Dr. Iván Núñez Gil. Anatomía coronaria básica - Coronariografía. Visualización de las arterias coronarias en las distintas proyecciones de la coronariografía.
Cytori CEO Chris Calhoun presents as part of the "Cardiovascular, AMI & PAD" panel on the Regenerative Medicine Insight Track at the Biotech Showcase on January 10, 2012
Estudio presentado por la Dra. Anna Toso en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
Estudio presentado por el Dr. Gilles Montalescot en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
Quirofano hibrido por Dr. Gerardo Sela.gerardo sela
Concepto de lo que es una Quirofano hibrido, es decir una sala de hemodinamia y un quirofano con lo mas sofisticado de ambas tecnologias para atencion de padecimientos que regularmente llevarian dos tiempos.
Anatomía coronaria básica - Coronariografía. Visualización de las arterias co...CardioTeca
Autor: Dr. Iván Núñez Gil. Anatomía coronaria básica - Coronariografía. Visualización de las arterias coronarias en las distintas proyecciones de la coronariografía.
Emmanouil S. Brilakis - CTO PCI Outcome associated with poor quality of the d...Euro CTO Club
16:53
CTO PCI Outcome associated with poor quality of the distal target vessel
Emmanouil Brilakis (Minneapolis - USA)
_____________________________________________
PARALLEL SESSION
Interventional CTO & Chip Research
Best CTO Publications 2022-23 (selected by the Editors of the Cardiology Interventional journals)
Auditorium Zubin Mehta - Friday 16:30 - 17:16
Chairpersons:
Davide Capodanno (Catania),
Carlo Di Mario (Florence),
Giuseppe Tarantini (Padua)
Panelist:
Roberto Diletti (Rotterdam - NL),
Giovanni Esposito (Naples),
Paul Knaapen (Amsterdam - NL),
Maksymilian Opolski (Warsaw - PL)
___________________________________________
15th Experts Live CTO,
EUROCTO Club meeting in partnership with the GISE CTO meeting.
September 8th - 9th, 2023
Florence, Italy
Important Trials of the Day & Basics of Biostatistics | IACTS SCORE 2020IACTSWeb
This presentation emphasizes on the importance of biostatistics in the interpretation, analysis and design of studies and trials in the daily life of an academic surgeon. It also sheds light on some important clinical trials of the present milieu that are playing a vital role in the course that cardiothoracic surgery is taking.
Courtesy of Dr. Prasanna Simha Mohan Rao, MS, MCh, DNB, PGDHHM. He presently serves as Professor and Unit Chief of Cardiothoracic and Vascular Surgery at Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru.
This presentation accompanies a video that is part of the lecture series of IACTS SCORE 2020 held at the SSSIHMS Whitefield, Bengaluru between 7th and 8th March, 2020.
Dra. Margaret Redfield. Congreso ACC 2013, Estados Unidos. RELAX: Inhibidor de la fosfodiesterasa-5 no mostró beneficio en la insuficiencia cardiaca con función ventricular preservada. Encuentre más presentaciones de este congreso en la página oficial de SOLACI: www.solaci.org/
La tromboaspiración se correlaciona con un menor índice de resistencia de la microcirculación. Dr. Dejan Orlic, MD. Congreso euroPCR 2013, Paris, Francia. Encuentre más presentaciones en la web de SOLACI: www.solaci.org/
Manejo peri-procedimiento en el paciente con PCI. Dr. Lluberas, Ricardo. Congreso SOLACI 2012, México. Encuentre más presentaciones en la web: www.solaci.org/
Disclosures: Full time employee of Abbott Vascular. Dra. Moreira Rebeca.SOLACI México Congress 2012. Find more presentations on the web site: www.solaci.org/
Reestenosis, Síndrome coronario agudo. Rol actual de los nuevos antiplaquetarios en el síndrome coronario agudo. Congreso SOLACI Chile 2011.Dr. Ramón Corbalán. Encuentre más presentaciones en la página www.solaci.org/
SOLACI Chile Congress 2011. Dr.Ajay Kirtane. Drug-Eluting Stents for Multivessel PCI: Indications and Outcomes. Find more presentations on the web site: www.solaci.org/
SOLACI Coverage: AHA 2012 Congress. Dr. Jay H. Traverse. Estudio TIME: Uso y duración de la infusión de células madre derivadas de médula ósea en la disfunción ventricular izquierda después de un infarto de miocardio.Find more presentations on our web http://solaci.org/es/aha_2012.php
SOLACI Coverage: AHA 2012 Congress. Dr. Esteban Lopez-de-Sa . PILOT trial: El estudio piloto de dos niveles de hipotermia en los sobrevivientes comatosos tras un paro cardiaco fuera del hospital. Find more presentations on our web http://solaci.org/es/aha_2012.php
Estudio presentado por la Dra. Alice Jacobs en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
Estudio presentado por el Dr. David Holmes en el último ACC.2013, realizado en San Francisco, Estados Unidos, los días 9, 10 y 11 de Marzo. Más presentaciones de este evento en www.solaci.org/es/coberturas.php
REVISÃO DE TEMAS DE INTERESSE: Intervenções Periféricas: “Isquemia Critica dos Membros Inferiores”. Intervenções Coronarias: “Angioplastia post-trombolíticos”. Caso clínico: “Procedimento em um caso com infarto agudo do miocárdio em choque cardiogênico”
REVISÃO DE TEMAS DE INTERESSE: Intervenções Coronarias: “Quando Indicar PCI em Múltiplos Vasos”, Intervenções Periféricas: “Doença Infrapoplítea”. Caso clínico: “Tratamento percutâneo de lesão em tronco de coronária esquerda com
acometimento bi-ostial”
Intervención Coronaria Percutánea en el IAM: MASTER Trial, AIDA STEMI-MRI Trial, POST Trial, STEMI-RADIAL Trial. Antiagregación y nefropatía por contraste: TRILOGY ACS Trial, ADAPT-DES One Year, POSEIDON Trial. Encuentre los últimos boletines en solaci.org/es/boletin-educativo.php
More from Sociedad Latinoamericana de Cardiología Intervencionista (20)
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
How to Give Better Lectures: Some Tips for Doctors
Revascularización miocárdica sin bomba; iguales resultados al año que la cirugía con bomba
1. CORONARY: The Coronary Artery Bypass
Grafting Surgery Off or On Pump
Revascularization Study
Results at 1 Year
André Lamy
Population Health Research Institute
Hamilton Health Sciences
McMaster University
Hamilton, CANADA
on behalf of the CORONARY Investigators
Disclosures: CORONARY was funded by a grant from the Canadian Institutes
of Health Research (CIHR).
2. Background
• Benefits and risks of performing CABG surgery on
beating heart (off pump) not clearly established.
• Meta-analyses of 59 trials involving 8961 pts
– No differences in major CV outcomes except strokes
• ROOBY (1 Year)
– Primary Outcome: Off-pump is worse (p=0.04)
– CV Deaths: Off-pump is worse (p=0.03)
2
3. CORONARY Trial Organization
• 79 centers in 19 countries
• 4,752 patients recruited between (November 2006
October 2011)
• Designed, coordinated, managed and data analysed
and reported by the Population Health Research
Institute, Hamilton Health Sciences and McMaster
University in Hamilton, Canada
• The data was monitored by independent DSMB
• Funded by Canadian Institutes of Health Research
3
4. Inclusion/Exclusion Criteria
• Inclusion Criteria
– Isolated CABG with median sternotomy
– One of the following:
1. Peripheral vascular disease
2. Cerebrovascular disease
3. Renal Insufficiency
4. Age ≥ 70 years
5. Age 60 -69 with at least one risk factor (diabetes, urgent
revascularization, smoker, LVEF ≤ 35%)
6. Age 55 -59 with at least two of the above risk factors
• Exclusions
– Additional cardiac procedure planned
– Contraindications to off-pump or on-pump CABG
– Emergency or re-do CABG
5
5. Qualifications of Surgeons
• Surgical expertise-based randomization
– > 2 years of experience as staff cardiac surgeon
and
– > 100 cases of one or both techniques
– Trainees were not allowed to be primary
operators
6
6. Primary Outcomes
• 1st Co-Primary Outcome
Composite of total mortality, stroke, non fatal myocardial
infarction, new renal failure at 30 days post randomization
results presented ACC 2012
results at 1 year
• 2nd Co-Primary Outcome
Composite of above outcomes plus repeat coronary
revascularization over 5 yrs of follow-up (expected 2016)
7
9. 1st Co-Primary Outcome (1 Year)
Off Pump On Pump Hazard p
% % Ratio 95% CI value
Primary Outcome
12.1 13.3 0.91 0.77-1.07 0.24
Death, Stroke, MI, Renal Failure
Components
Death 5.1 5.0 1.03 0.80-1.32
Stroke 1.5 1.7 0.90 0.57-1.41
Non Fatal MI 6.8 7.5 0.90 0.73-1.12
New Renal Failure 1.3 1.3 0.97 0.59-1.60
14
10. Death/MI/Stroke/New Renal Failure
0.20
0.15 at 1 Year
On Pump CABG
Cumulative Event Rate
Off Pump CABG
0.10
HR 0.91
0.05
95% CI 0.77-1.07
p value 0.24
0.0
0 3 6 9 12
15
11. Other Outcomes at 1 year
Off Pump On Pump Hazard
95% CI p value
% % Ratio
Cardiovascular Mortality 4.2 4.0 1.03 0.78-1.37 0.83
Angina 1.0 0.9 1.05 0.58-1.88 0.87
PCI 1.1 0.8 1.43 0.79-2.57 0.23
Re-do CABG 0.3 0.04 7.00 0.86-57.0 0.07
PCI/Re-do CABG 1.4 0.8 1.66 0.95-2.89 0.07
Primary Outcome per Protocol 11.5 13.2 0.86 0.73-1.02 0.08
16
12. Primary Outcome between
31 days and 1 Year
Off Pump On Pump Hazard p
% % Ratio 95% CI value
Primary Outcome
2.6 3.2 0.79 0.55-1.13 0.19
Death/MI/Stroke/Renal Failure
Components
Death 2.1 2.3 0.87 0.58-1.31
Stroke 0.5 0.6 0.83 0.36-1.92
Non Fatal MI 0.2 0.4 0.50 0.15-1.65
New Renal Failure 0.1 0.2 0.50 0.09—2.71
17
13. Other Outcomes between
31 days and 1 Year
Off Pump On Pump Hazard
95% CI p value
% % Ratio
Cardiovascular Mortality 1.5 1.5 1.06 0.65-1.73 0.82
Angina 0.8 0.7 1.13 0.56-2.26 0.74
PCI 0.7 0.6 1.15 0.55-2.41 0.72
Re-do CABG <0.1 0 0.99
PCI/Re-do CABG 0.7 0.6 1.22 0.59-2.54 0.59
18
18. Conclusions
• At 1 Year there was no difference between Off
pump CABG and On pump CABG:
– Primary Outcome
– Individual components of the Primary Outcome
– Revascularization procedures
– Quality of Life
– Neurocognitive functions
23
20. Steering Committees
A. Lamy (Co-PI) P.J. Devereaux J. Murkin
D.P. Taggart D. Prabhakaran R.J. Novick
A.R. Akar S.E. Fremes E. Paolasso
A. Avezum S. Hu L. Piegas
R. Cartier F. Lanas Z. Straka
S. Chocron P.J. Lopez S. Yusuf (co-PI)
25
21. Final Recruitment by Country
4752 patients from 79 sites in 19 countries
Netherlands (27)
Sweden (56)
United Kingdom (227)
Canada (830)
France (4) Czech Republic (298)
Italy (48) Estonia (91)
Turkey (132)
USA (68) Ukraine (11)
China (781)
India (1307)
Colombia (57)
Brazil (358)
Australia (29)
Chile (137) Uruguay (34)
Argentina (257)
26